Showing results (71-80 of 180) with videos related to
Sort By:
Pageof 18
American Journal of Hematology|January 2, 2024
Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working PartyNour Moukalled, Myriam Labopin, Jurjen Versluis, et al.Bone Marrow Transplantation|June 19, 2025
Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AMLGuillaume Dachy, Myriam Labopin, Gérard Socié, et al.Annals of the Rheumatic Diseases|November 18, 2017
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Léa Rouxel, Thomas Barnetche, et al.Bone Marrow Transplantation|August 20, 2024
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMTArnon Nagler, Myriam Labopin, Urpu Salmenniemi, et al.The Lancet. Rheumatology|March 29, 2025
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?Marc Scherlinger, Gaetane Nocturne, Marko Radic, et al.Bone Marrow Transplantation|April 13, 2024
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Eleonora Mauric, Alice Tison, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2025
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 TrialMohamad Mohty, Gerard Socié, Jeff Szer, et al.Blood|December 17, 2015
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHDAna C Alho, Haesook T Kim, Marie J Chammas, et al.Blood Neoplasia|April 6, 2026
Late outcomes after posttransplant cyclophosphamide-based GVHD prophylaxis in patients with AML: an ALWP-EBMT studyEduardo Rodríguez-Arbolí, Allain-Thibeault Ferhat, Anna Maria Raiola, et al.Pageof 18